GT Biopharma, Inc. filed an 8-K on June 10, 2025, reporting a $20 million common stock purchase agreement with investors, which includes an amendment allowing them to own up to 9.99% of shares. Additionally, David C. Mun-Gavin was appointed as a non-employee director and chair of the Compensation Committee on the same day.